Candel Therapeutics, Inc. CADL Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s operating lease right-of-use assets in other assets?
- Candel Therapeutics, Inc. (CADL) reported operating lease right-of-use assets in other assets of $1.57M in Q1 2026.
- How has Candel Therapeutics, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
- Candel Therapeutics, Inc.'s operating lease right-of-use assets in other assets increased by 235.3% year-over-year, from $468K to $1.57M.
- What is the long-term trend for Candel Therapeutics, Inc.'s operating lease right-of-use assets in other assets?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s operating lease right-of-use assets in other assets has grown at a 16.3% compound annual growth rate (CAGR), from $1.06M to $1.66M.